Clinical Trial Update: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for taselisib plus enzalutamide in androgen receptor positive triple-negative metastatic breast cancer; trial phases 1/2; status terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative
• Estrogen Receptor Positive
• Progesterone Receptor Negative
• Progesterone Receptor Positive
• Triple-negative Breast Carcinoma

Drugs mentioned

• Enzalutamide (enzalutamide)
• Taselisib (GDC-0032)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-05-07